Health Ongoing Trials Enhance Use of CDK4/6 Inhibitors in Breast Cancer The use of CDK4/6 inhibitors remains pivotal in treating hormone receptor (HR)-positive metastatic breast cancer, both HER2-negative and HER2-positive, especially for patients experiencing visceral... Editorial30 August, 2025
Top Stories Thoma Bravo Eyes Dayforce Buyout as Shares Surge UPDATE: Thoma Bravo is reportedly on the verge of taking Dayforce private, with a deal announcement expected in the coming weeks. Shares of the... Editorial18 August, 2025